• Home
  • >
  • Transgene Biotek Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/transgene-biotek-ltd.png Logo

Transgene Biotek Ltd Financial Statement

Transgene Biotek Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Dec 2023Sep 2023Jun 2023
Revenue0.090.090.14
Operating Expense0.150.170.22
Net Profit-0.12-0.13-0.13
Net Profit Margin-133.33-144.44-92.86
Earning Per Share-0.02-0.02-0.17
EBIDTA-0.07-0.08-0.08
Effective Tax RateTBATBATBA

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Transgene Biotek Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual0.060.090.17
Operating Expenses Annual1.110.550.7
Operating Profit Annual-0.88-0.25-0.26
Interest Annual0.180.230.27
Depreciation0.090.180.2
Net Profit Annual-6.01-10.4-10.43
Tax AnnualTBATBATBA

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Transgene Biotek Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning0.020.010.04
Cash Flow from OperationsTBA0.10.01
Cash Flow from Investing-0.01-0.1-0.03
Cash Flow from FinancingTBATBATBA
Cash Flow at the EndTBA0.020.02

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Transgene Biotek Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual8.3213.2623.19
Total Current Assets Annual0.890.70.65
Non Current Assets Annual141.46146.4156.23
Total Shareholders Funds Annual11.3717.3822.24
Total Assets Annual142.36147.1156.88

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Transgene Biotek Ltd Earning Calls
Dec 2023
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Transgene Biotek Ltd has a market capitalization of 18.87 Cr. Value Research classifies it as a Micro-Cap company.

No, Transgene Biotek Ltd is not debt-free with a debt-to-equity ratio of 1.15.

In FY 2023, Transgene Biotek Ltd recorded a total revenue of approximately 0.06 Cr marking a significant milestone in the company's financial performance.

Transgene Biotek Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.3% and -0.5% annually, respectively..

Transgene Biotek Ltd's current PE ratio is -3.14.

Transgene Biotek Ltd's ROCE averaged -29.1% from the FY ending March 2021 to 2023, with a median of -29.7%. It peaked at -23.5% in March 2023, reflecting strong capital efficiency over the period..

Transgene Biotek Ltd's latest EBIT is Rs. -5.83 Cr, surpassing the average EBIT of Rs. -8.72 Cr over the 5 years..